Table 3.

Identification of independent predictors of the combined end point selected by Cox regression analysis

	Unadjusted Hazard			Sig.	Adjusted Hazard			p
	Ratio	95% Confidence Interval			Ratio	95% Confidence Interval
		Lower	Upper			Lower	Upper
eGFR (MDRD formula)	0.97	0.63	0.98	<0.001	0.99	0.98	1.0	0.004
Clopidogrel low response (RPA >75% percentile)	2.08	1.42	3.03	<0.001	1.64	1.06	2.54	0.026
Diabetes mellitus	2.17	1.49	3.16	<0.001	1.68	1.1	2.57	0.02
ACS	2.2	1.49	3.26	<0.001	1.78	1.14	2.77	0.01
Impaired left ventricular function	2.42	1.64	3.59	<0.001	1.66	1.04	2.66	0.04
ACE inhibitors	0.75	0.48	1.17	0.203	0.68	0.38	1.23	0.21
Pretreatment with aspirin	0.9	0.62	1.29	0.56	0.98	0.63	1.52	0.91
Pretreatment with clopidogrel	0.63	0.31	1.3	0.21	0.34	0.15	0.77	0.01
GPIIb-IIIa inhibitors (abciximab)	0.81	0.45	1.44	0.46	0.8	0.42	1.52	0.49
AT1 blockers	1.07	0.61	1.87	0.819	0.84	0.39	1.79	0.84
Beta blockers	0.31	0.19	0.50	<0.001	0.53	0.29	0.94	0.03
Calcium-channel blockers	0.99	0.59	1.67	0.98	0.75	0.4	1.39	0.36
Diuretics	1.22	0.84	1.78	0.29	1.02	0.67	1.54	0.94
Statins	0.45	0.28	0.7	<0.001	0.67	0.39	1.16	0.15
Age	1.04	1.02	1.06	<0.001	1.00	0.98	1.03	0.7
Tobacco use	0.65	0.44	0.98	0.039	0.95	0.59	1.53	0.82
Arterial hypertension	0.66	0.44	1.01	0.058	0.62	0.39	1.00	0.052
Gender	1.13	0.76	1.7	0.54	0.84	0.52	1.37	0.49
Interaction effect CKD group 1, clopidogrel low responsea	2.08	1.61	2.67	<0.001	1.37	1.13	1.66	0.001

ACE, angiotensin-converting enzyme; Sig., significance; ACS, acute coronary syndrome.

^aWhen adjusted for diabetes mellitus, acute coronary syndromes, impaired left ventricular, gender arterial hypertension, tobacco use, age, cardiovascular comedication, antiplatelet pretreatment, clopidogrel low response, and age.